Company Profiles

driven by the PitchBook Platform

Xeris Pharmaceuticals

Xeris Pharmaceuticals
2005 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series C LATEST DEAL TYPE
$71M LATEST DEAL AMOUNT
14 INVESTORS
Description

Developer of a glucagon rescue pen for emergency treatment of severe hypoglycemia. The company develops injectable drugs based on its non-aqueous XeriJect and XeriSol formulation and delivery platforms.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 180 North LaSalle Street
  • Suite 1800
  • Chicago, IL 60601
  • United States

+1 (844) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Xeris Pharmaceuticals’s full profile, request a free trial.

Xeris Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series C) 17-May-2017 $71M 000.00 00000 Completed Clinical Trials - Phase 3
6. Later Stage VC (Series B) 08-Jan-2015 000.00 000.00 000.00 Completed Clinical Trials - Phase 2
5. Grant 01-Feb-2013 000.00 00.000 Completed Generating Revenue
4. Grant 31-Jul-2012 00000 00.000 Completed Generating Revenue
3. Early Stage VC (Series A) 11-Oct-2011 00.000 00.000 00.000 Completed Generating Revenue
2. Seed Round 29-Nov-2005 $55K $55K Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Xeris Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 1,864,797 $0.000100 8% $1.02 $1.02 1x $1.02 6.84%
To view this company’s complete Cap Table, request access »

Xeris Pharmaceuticals Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Annex Ventures Venture Capital Minority 000 0000 000000 0
Asahi Kasei Corporate Venture Capital Corporate Venture Capital Minority 000 0000 000000 0
Bay City Capital Venture Capital Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Mérieux Développement Growth/Expansion Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Xeris Pharmaceuticals Executive Team (7)

Name Title Board
Seat
Contact
Info
Paul Edick Chief Executive Officer, Board Member & President
Yash Sabharwal Ph.D Chief Operating Officer & Chief Financial Officer
Phillip Johnson Chief Financial Officer
Steven Prestrelski Ph.D Chief Scientific Officer, Co-Founder & Director
John Kinzell Ph.D Executive Vice President, Corporate Development, Director & Co-Founder

2 Former Executives

You’re viewing 5 of 7 executives. Get the full list »

Xeris Pharmaceuticals Board Members (6)

Name Representing Role Since Contact
Info
Navneet Puri Ph.D Self Board Member 000 0000
Robert Faulkner Redmile Group Board Member 000 0000
Shane Brisbin Self Director 000 0000

3 Former Board Members

You’re viewing 3 of 6 board members. Get the full list »